HN2010002157A - Antagonistas de la trayectoria hedgehog de ftalazina disustituida - Google Patents

Antagonistas de la trayectoria hedgehog de ftalazina disustituida

Info

Publication number
HN2010002157A
HN2010002157A HN2010002157A HN2010002157A HN2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A
Authority
HN
Honduras
Prior art keywords
hedgehog
antagonists
ftalazina
disttituted
history
Prior art date
Application number
HN2010002157A
Other languages
English (en)
Spanish (es)
Inventor
Philip Arthur Hipsikind
Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2010002157A publication Critical patent/HN2010002157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HN2010002157A 2008-04-29 2010-10-21 Antagonistas de la trayectoria hedgehog de ftalazina disustituida HN2010002157A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4872908P 2008-04-29 2008-04-29

Publications (1)

Publication Number Publication Date
HN2010002157A true HN2010002157A (es) 2014-09-08

Family

ID=40846962

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010002157A HN2010002157A (es) 2008-04-29 2010-10-21 Antagonistas de la trayectoria hedgehog de ftalazina disustituida

Country Status (22)

Country Link
US (1) US7981892B2 (enExample)
EP (1) EP2294061A2 (enExample)
JP (1) JP5442717B2 (enExample)
KR (1) KR101260116B1 (enExample)
CN (1) CN102066353B (enExample)
AU (1) AU2009241561B2 (enExample)
BR (1) BRPI0911618A2 (enExample)
CA (1) CA2723042A1 (enExample)
CO (1) CO6300945A2 (enExample)
CR (1) CR11741A (enExample)
DO (1) DOP2010000302A (enExample)
EA (1) EA201071248A1 (enExample)
EC (1) ECSP10010577A (enExample)
HN (1) HN2010002157A (enExample)
IL (1) IL208211A0 (enExample)
MA (1) MA32349B1 (enExample)
MX (1) MX2010011948A (enExample)
MY (1) MY159491A (enExample)
NZ (1) NZ588001A (enExample)
UA (1) UA102250C2 (enExample)
WO (1) WO2009134574A2 (enExample)
ZA (1) ZA201006695B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101260116B1 (ko) 2008-04-29 2013-05-02 일라이 릴리 앤드 캄파니 이치환된 프탈라진 헤지호그 경로 길항제
CA2742539C (en) 2008-11-03 2014-05-06 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
ES2392759T3 (es) 2008-11-17 2012-12-13 Eli Lilly And Company Piridazina tetrasustituida como antagonistas de la vía Hedgehog.
EA018372B1 (ru) 2008-11-17 2013-07-30 Эли Лилли Энд Компани Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AU2010322114B2 (en) * 2009-11-18 2014-07-31 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
CA2878082A1 (en) 2012-09-17 2014-03-20 Duke University Smoothened modulators and methods of use thereof
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
KR20230107568A (ko) 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법
US20240124451A1 (en) * 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
MY117098A (en) 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO1999052534A1 (en) 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
EP1997494A3 (en) 2002-04-22 2009-06-10 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
JP5221952B2 (ja) 2004-05-08 2013-06-26 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド ３−アリール−５，６−ジ置換ピリダジン類
KR20150002863A (ko) * 2004-09-02 2015-01-07 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
DK2137162T3 (en) * 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
CA2690378A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
KR101260116B1 (ko) 2008-04-29 2013-05-02 일라이 릴리 앤드 캄파니 이치환된 프탈라진 헤지호그 경로 길항제
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2742539C (en) 2008-11-03 2014-05-06 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
ES2392759T3 (es) 2008-11-17 2012-12-13 Eli Lilly And Company Piridazina tetrasustituida como antagonistas de la vía Hedgehog.
EA018372B1 (ru) 2008-11-17 2013-07-30 Эли Лилли Энд Компани Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
ECSP10010577A (es) 2010-11-30
CO6300945A2 (es) 2011-07-21
KR101260116B1 (ko) 2013-05-02
US20110046143A1 (en) 2011-02-24
CR11741A (es) 2011-01-05
EP2294061A2 (en) 2011-03-16
ZA201006695B (en) 2012-09-26
JP2011527666A (ja) 2011-11-04
CN102066353A (zh) 2011-05-18
MA32349B1 (fr) 2011-06-01
AU2009241561A1 (en) 2009-11-05
AU2009241561B2 (en) 2013-05-16
WO2009134574A2 (en) 2009-11-05
BRPI0911618A2 (pt) 2019-09-24
JP5442717B2 (ja) 2014-03-12
UA102250C2 (ru) 2013-06-25
MX2010011948A (es) 2010-12-14
MY159491A (en) 2017-01-13
CN102066353B (zh) 2013-12-11
CA2723042A1 (en) 2009-11-05
NZ588001A (en) 2012-06-29
WO2009134574A3 (en) 2014-09-04
IL208211A0 (en) 2010-12-30
US7981892B2 (en) 2011-07-19
DOP2010000302A (es) 2010-11-15
EA201071248A1 (ru) 2011-06-30
KR20100126580A (ko) 2010-12-01

Similar Documents

Publication Publication Date Title
HN2010002157A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
CL2019002067A1 (es) Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. (divisional solicitud 201803050).
MX386187B (es) Compuestos de benzo[b]tiofeno como agonistas de sting.
CR20120051A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CY1120054T1 (el) Ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νευρολογικων και ψυχολογικων διαταραχων
BRPI0912542A2 (pt) derivados de ácido 3,5-diamino-cloro-pirazina-2-carboxílico e seu uso como bloqueadores do canal de sódio epitelial para o tratamento de vias aéreas.
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
MX378957B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
MX372722B (es) Sulfonamidas de aza-aril 1h-pirazol-1-il benceno
UY34539A (es) Heteroarilos y usos de los mismos
MX339709B (es) Antagonistas de wnt y metodos de tratamiento y analisis.
UY29186A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
MX2012013945A (es) Nuevas formas de rifaximina y usos de las mismas.
LT3045474T (lt) Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija
UY30835A1 (es) 8-alquinilxantinas y derivados
EA201200578A1 (ru) Сульфоксидные производные для лечения опухолей
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
ECSP11011482A (es) Piperidinas sustituidas
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.